



Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer

Guest Editors:

Prof. Dr. Rafael Coveñas Rodríguez

Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neuroscience of Castilla and León (INCYL), University of Salamanca, c/ Pintor Fernando Gallego 1, 37007 Salamanca, Spain

Dr. Miguel Muñoz Sáez

Hospital Infantil Virgen del Rocío, Unidad de Cuidados Intensivos Pediátricos, Av. Manuel Siurot s/n, 41013 Sevilla, Spain

Deadline for manuscript submissions:

closed (31 December 2021)

Message from the Guest Editors

In recent years, the knowledge on the involvement of peptides in cancer has attracted increasing interest. This has opened up new research lines and possibilities to improve cancer diagnosis and to explore new therapeutic strategies targeting tumor-specific molecular derangements. It is important to identify new molecular targets to block tumor development and new compounds capable of specifically destroying cancer cells must be investigated.

The neurokinin-1 receptor is a new promising target in cancer treatment and neurokinin-1 receptor antagonists are a promising generation of antitumor drugs. To increase the current knowledge on the role played by the substance P/neurokinin-1 receptor system in cancer, this Special Issue will highlight basic, pre-clinical and clinical aspects on the involvement of the substance P/neurokinin-1 receptor system in cancer development and it will be also focused on the promising use of neurokinin-1 receptor antagonists as a new antitumor strategy.

Detailed information of this special issue "Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer" can be found at below link:

https://www.mdpi.com/journal/cancers/special_issues/SP





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)